Eton Pharmaceuticals shares are trading lower after the FDA issued complete response letter to dehydrated alcohol injection for methanol poisoning.
Portfolio Pulse from Benzinga Newsdesk
Eton Pharmaceuticals' shares are trading lower after the FDA issued a complete response letter to the company's dehydrated alcohol injection for methanol poisoning.

June 28, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eton Pharmaceuticals' stock price is expected to decrease in the short term due to the FDA's complete response letter to its dehydrated alcohol injection for methanol poisoning.
The FDA's complete response letter is typically a form of rejection, which means Eton Pharmaceuticals' dehydrated alcohol injection for methanol poisoning may not be approved. This could negatively impact the company's future revenues and profitability, leading to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100